Prognostic role of histone deacetylase 10 in colorectal cancer: Strengths and ‎gaps

Figure 1 Schematic overview of histone deacetylase 10’s multifaceted role in colorectal cancer progression and therapy response. A: Downregulation of histone deacetylase 10 (HDAC10) is proposed to reshape the tumor microenvironment, but its precise effects on CD8⁺ T cell activation, regulatory T cells, and myeloid-derived suppressor cells remain to be elucidated; B: Pharmacological inhibition of HDAC10 (e.g., DKFZ-748) leads to chemosensitization of colorectal cancer cells, yet the clinical benefit of this approach vs pan-HDAC inhibition is undetermined; C: HDAC10 suppression is associated with increased p53 and reduced programmed death ligand 1 expression; however, ‎the mechanistic pathway remains unclear, especially in the context of immune cell proliferation ‎and immune evasion. Orange question marks indicate hypothetical mechanisms that remain to ‎experimentally validate. HDAC10: Histone deacetylase 10; PDL1: Programmed death ligand 1.